27926483|t|The metastasis suppressor CD82/KAI1 inhibits fibronectin adhesion - induced epithelial-to-mesenchymal transition in prostate cancer cells by repressing the associated integrin signaling
27926483|a|The transmembrane protein CD82/KAI1 suppresses the metastatic potential of various cancer cell types. Moreover, decrease or loss of CD82 expression is closely associated with malignancy and poor prognosis in many human cancers including prostate cancer. Despite intense scrutiny, the mechanisms underlying the metastasis - suppressing role of CD82 are still not fully understood. Here, we found that a fibronectin matrix induced mesenchymal phenotypes in human prostate cancer cells with no or low CD82 expression levels. However, high CD82 expression rendered prostate cancer cells to have intensified epithelial characteristics upon fibronectin engagement, along with decreased cell motility and invasiveness. The CD82 function of inhibiting fibronectin - induced epithelial-to-mesenchymal transition (EMT) was dependent not only on CD82 interactions with fibronectin - binding α3β1 / α5β1 integrins but also on the integrin-mediated intracellular signaling events. Notably, CD82 attenuated the FAK-Src and ILK pathways downstream of the fibronectin - receptor integrins. Immunofluorescence staining of human prostate cancer tissue specimens illustrated a negative association of CD82 with EMT -related gene expression as well as prostate malignancy. Altogether, these results suggest that CD82 suppresses EMT in prostate cancer cells adhered to the fibronectin matrix by repressing adhesion signaling through lateral interactions with the associated α3β1 and α5β1 integrins, leading to reduced cell migration and invasive capacities.
27926483	4	25	metastasis suppressor	T028	C0949486
27926483	26	35	CD82/KAI1	T116,T129	C1528437
27926483	36	44	inhibits	T052	C3463820
27926483	45	56	fibronectin	T116,T123	C0016055
27926483	57	65	adhesion	T043	C0007577
27926483	68	75	induced	T169	C0205263
27926483	76	112	epithelial-to-mesenchymal transition	T043	C1523298
27926483	116	124	prostate	T023	C0033572
27926483	125	137	cancer cells	T025	C0334227
27926483	141	151	repressing	T169	C0205245
27926483	156	166	associated	T080	C0332281
27926483	167	185	integrin signaling	T044	C1512812
27926483	190	211	transmembrane protein	T116	C0021699
27926483	212	221	CD82/KAI1	T116,T129	C1528437
27926483	222	232	suppresses	T169	C1260953
27926483	237	247	metastatic	T169	C1522484
27926483	248	257	potential	T080	C3245505
27926483	269	280	cancer cell	T025	C0334227
27926483	281	286	types	T080	C0332307
27926483	298	306	decrease	T081	C0547047
27926483	310	314	loss	T081	C1517945
27926483	318	322	CD82	T116,T129	C1528437
27926483	323	333	expression	T045	C1171362
27926483	345	360	associated with	T080	C0332281
27926483	361	371	malignancy	T191	C4282132
27926483	376	390	poor prognosis	T033	C0278252
27926483	399	404	human	T016	C0086418
27926483	405	412	cancers	T191	C0006826
27926483	423	438	prostate cancer	T191	C0376358
27926483	470	480	mechanisms	T169	C0441712
27926483	496	506	metastasis	T046	C4255448
27926483	509	520	suppressing	T169	C1260953
27926483	529	533	CD82	T116,T129	C1528437
27926483	588	599	fibronectin	T116,T123	C0016055
27926483	600	606	matrix	T024	C0015350
27926483	607	614	induced	T169	C0205263
27926483	615	626	mesenchymal	T080	C1513143
27926483	627	637	phenotypes	T032	C0031437
27926483	641	646	human	T016	C0086418
27926483	647	655	prostate	T023	C0033572
27926483	656	668	cancer cells	T025	C0334227
27926483	684	688	CD82	T116,T129	C1528437
27926483	689	699	expression	T045	C1171362
27926483	700	706	levels	T080	C0441889
27926483	722	726	CD82	T116,T129	C1528437
27926483	727	737	expression	T045	C1171362
27926483	747	755	prostate	T023	C0033572
27926483	756	768	cancer cells	T025	C0334227
27926483	789	799	epithelial	T080	C0221908
27926483	800	815	characteristics	T080	C1521970
27926483	821	832	fibronectin	T116,T123	C0016055
27926483	856	865	decreased	T081	C0205216
27926483	866	879	cell motility	T040	C0007608
27926483	884	896	invasiveness	T046	C0920779
27926483	902	906	CD82	T116,T129	C1528437
27926483	907	915	function	T169	C0542341
27926483	919	929	inhibiting	T052	C3463820
27926483	930	941	fibronectin	T116,T123	C0016055
27926483	944	951	induced	T169	C0205263
27926483	952	988	epithelial-to-mesenchymal transition	T043	C1523298
27926483	990	993	EMT	T043	C1523298
27926483	1021	1025	CD82	T116,T129	C1528437
27926483	1026	1038	interactions	T044	C0872079
27926483	1044	1055	fibronectin	T116,T123	C0016055
27926483	1058	1065	binding	T044	C0033618
27926483	1066	1070	α3β1	T116,T192	C0246766
27926483	1073	1087	α5β1 integrins	T116,T192	C1138422
27926483	1104	1145	integrin-mediated intracellular signaling	T044	C1155451
27926483	1146	1152	events	T051	C0441471
27926483	1163	1167	CD82	T116,T129	C1528437
27926483	1168	1178	attenuated	T052	C0599946
27926483	1183	1190	FAK-Src	T044	C1148560
27926483	1195	1207	ILK pathways	T044	C1148560
27926483	1208	1218	downstream	T082	C0522506
27926483	1226	1237	fibronectin	T116,T123	C0016055
27926483	1240	1258	receptor integrins	T116,T129,T192	C0021701
27926483	1260	1278	Immunofluorescence	T059	C0079603
27926483	1279	1287	staining	T059	C0487602
27926483	1291	1296	human	T016	C0086418
27926483	1297	1312	prostate cancer	T191	C0376358
27926483	1313	1329	tissue specimens	T024	C1292533
27926483	1344	1352	negative	T033	C0205160
27926483	1353	1364	association	T080	C0439849
27926483	1368	1372	CD82	T116,T129	C1528437
27926483	1378	1381	EMT	T043	C1523298
27926483	1391	1406	gene expression	T045	C0017262
27926483	1418	1426	prostate	T023	C0033572
27926483	1427	1437	malignancy	T191	C4282132
27926483	1478	1482	CD82	T028	C0812444
27926483	1483	1493	suppresses	T169	C1260953
27926483	1494	1497	EMT	T043	C1523298
27926483	1501	1509	prostate	T023	C0033572
27926483	1510	1522	cancer cells	T025	C0334227
27926483	1538	1549	fibronectin	T116,T123	C0016055
27926483	1550	1556	matrix	T024	C0015350
27926483	1560	1570	repressing	T169	C0205245
27926483	1571	1589	adhesion signaling	T169	C2984273
27926483	1598	1605	lateral	T082	C0205093
27926483	1606	1618	interactions	T169	C1704675
27926483	1628	1638	associated	T080	C0332281
27926483	1639	1643	α3β1	T116,T192	C0246766
27926483	1648	1662	α5β1 integrins	T116,T192	C1138422
27926483	1675	1682	reduced	T080	C0392756
27926483	1683	1697	cell migration	T043	C1622501
27926483	1702	1710	invasive	T046	C0920779
27926483	1711	1721	capacities	T081	C1516240